VisionPoint Advisory Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

VisionPoint Advisory Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-403	Closed	-$41.1K	–	841
2023 Q2	$41.1K	Buy	+403	New	+$38.1K	0.02%	228

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

VisionPoint Advisory Group's RETA Position: Q3 2023 in Review

VisionPoint Advisory Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 403 shares — an estimated $41.1K sold.

VisionPoint Advisory Group first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $41.1K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

VisionPoint Advisory Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
VisionPoint Advisory Group sold 403 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $41.1K.
VisionPoint Advisory Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
VisionPoint Advisory Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $41.1K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on VisionPoint Advisory Group's 13F filing for Q3 2023, filed 6 Dec 2023.